Case Report: Opsoclonus-Myoclonus Syndrome Associated With Contactin-Associated Protein-Like 2 and Acetylcholine Receptor Autoantibodies in the Setting of Non-Small Cell Lung Carcinoma
Restricted accessCase reportFirst published online January, 2022
Case Report: Opsoclonus-Myoclonus Syndrome Associated With Contactin-Associated Protein-Like 2 and Acetylcholine Receptor Autoantibodies in the Setting of Non-Small Cell Lung Carcinoma
Opsoclonus myoclonus syndrome (OMS) is a rare immune-mediated paraneoplastic or para/-post-infectious syndrome characterized by “dancing” eye movements, myoclonus, and ataxia. Neuropsychiatric symptoms have also been reported. Without treatment, OMS may progress to further neurological impairment and even death. Autoimmune attack of CNS structures in OMS is most commonly mediated by anti-Ri (also known as ANNA2) IgG antibodies, with additional findings implicating antibodies targeting various neurotransmitter receptors. Prompt immunotherapy and neoplasm treatment may result in improvement. We report a novel association of Contactin-Associated Protein-Like 2 (Caspr2) antibodies occurring in association with paraneoplastic OMS. While breast cancer and small cell lung cancer (SCLC) are more commonly associated with OMS among adults, we characterize a novel association between Caspr2 antibody in a patient with mixed non-small cell and small cell lung carcinoma.
PranzatelliMRTateEDMcGeeNR. Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study. Front Neurol. 2017;8:468.
2.
TateEDAllisonTJPranzateMRVerhuSJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs. 2005;22(1):8–19.
3.
BatallerLGrausFSaizAVilchezJJ, et al.Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus–myoclonus. Brain. 2001;124(2):437–443.
4.
KlaasJPAhlskogJEPittockSJ, et al.Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol. 2012;69(12):1598–1607.
5.
BerridgeGMenassaDAMoloneyT, et al.Glutamate receptor δ2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome. Neurology. 2018;91(8):e714–e23.
6.
ArmanguéTSabaterLTorres-VegaE, et al.Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol. 2016;73(4):417–424.
TsutadaTIzumiTMurakamiT. Correlation of clinical improvement with pontine lesions in opsoclonus-myoclonus syndrome. Osaka City Med J. 1996;42(1):53–60.
13.
MatthayKKBlaesFHeroB, et al.Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett. 2005;228(1):275–282.
ZouYZhangW-FLiuH-Y, et al.Structure and function of the contactin-associated protein family in myelinated axons and their relationship with nerve diseases. Neural Regen Res. 2017;12(9):1551–1558.
21.
PattersonKRDalmauJLancasterE. Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia. Ann Neurol. 2018;83(1):40–51.
22.
DawesJMWeirGAMiddletonSJ, et al.Immune or genetic-mediated disruption of CASPR2 causes pain hypersensitivity due to enhanced primary afferent excitability. Neuron. 2018;97(4):806–822.e10.
23.
van SonderenAAriñoHPetit-PedrolM, et al.The clinical spectrum of caspr2 antibody-associated disease. Neurology. 2016;87(5):521–528.
AndersonJGJaySJSchweerHMAndersonMM. Physician utilization of computers in medical practice: policy implications based on a structural model. Soc Sci Med. 1986;23(3):259–267.
26.
VerninoSLowPAFealeyRDStewartJDFarrugiaGLennonVA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med. 2000;343(12):847–855.
27.
McKeonAPittockSJGlassGA, et al.Whole-body tremulousness: isolated generalized polymyoclonus. Arch Neurol. 2007;64(9):1318–1322.
28.
KhanliHMStrongERichardsonP. A case of opsoclonus-myoclonus syndrome with positive serum antibody against ganglionic (Alpha-3) acetylcholine receptor (774). Neurology. 2020;94(15 Supplement):774.
